NCT06114511进行中（未招募）1 期
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 78
- 试验地点
- 2
- 主要终点
- Phase II: Objective Response Rate (ORR)
研究概览
简要总结
This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent and follow the requirements of the protocol.
- •No gender limit.
- •Age: ≥18 years old and ≤75 years old.
- •expected survival time ≥3 months.
- •Histologically or cytologically confirmed, unresectable locally advanced or metastatic non-small cell lung cancer.
- •Confirmed known HER2-sensitive mutations, investigator-confirmed previous testing results, and trial site laboratory testing results were acceptable.
- •Patients in the advanced stage who had received platinum-based chemotherapy and immunotherapy concurrent or sequential therapy were unable to tolerate standard treatment or had disease progression during or after treatment.
- •Consent to provide archived tumor tissue or fresh tissue samples from primary or metastatic sites within 2 years for biomarker testing; Participants who were unable to provide tumor tissue samples could be enrolled if they met other inclusion and
排除标准
- •after evaluation by investigators.
- •Must have at least one measurable lesion according to RECIST v1.1 definition.
- •ECOG score 0 or
- •Toxicity of previous antineoplastic therapy has returned to grade 1 or less as defined by NCI-CTCAE v5.0 .
- •No severe cardiac dysfunction, left ventricular ejection fraction ≥50%.
- •Organ function levels must meet the requirements.
- •Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN.
- •Urine protein ≤2+ or ≤1000mg/24h.
- •For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the start of treatment, serum/urine pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
- •Exclusion Criteria:
- •Received chemotherapy, biological therapy, immunotherapy or other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.).
- •Prior treatment with an ADC drug containing a camptothecin derivative (topoisomerase I inhibitor) as a toxin.
- •Presence of other gene mutations for targeted drug therapy.
- •A history of severe cardiovascular and cerebrovascular diseases.
- •Active autoimmune or inflammatory diseases.
- •Patients with other malignant tumors within 5 years before the first administration.
- •Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded.
- •Patients with poorly controlled pericardial effusion, pleural effusion, peritoneal effusion, or pelvic effusion with clinical symptoms were judged by the investigator to be ineligible for enrollment.
- •Hypertension poorly controlled by antihypertensive drugs (systolic BP > 150 mmHg or diastolic blood pressure > 100 mmHg).
- •Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases.
- •Patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases). .
- •Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D
- •Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
- •Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > lower detection limit).
- •Active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.
- •Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of the last dose).
- •Pregnant or lactating women.
- •Other circumstances considered by the investigator to be inappropriate for participation in the trial.
研究组 & 干预措施
BL-M07D1
Experimental
Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: BL-M07D1 (Drug)
结局指标
主要结局
Phase II: Objective Response Rate (ORR)
时间窗: Up to approximately 24 months
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
Phase Ib: Recommended Phase II Dose (RP2D)
时间窗: Up to 21 days after the first dose
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M07D1.
次要结局
- Progression-free Survival (PFS)(Up to approximately 24 months)
- Cmax(Up to 21 days after the first dose)
- Treatment-Emergent Adverse Event (TEAE)(Up to approximately 24 months)
- Phase Ib: Objective Response Rate (ORR)(Up to approximately 24 months)
- Disease Control Rate (DCR)(Up to approximately 24 months)
- Tmax(Up to 21 days after the first dose)
- Ctrough(Up to 21 days after the first dose)
- Duration of Response (DOR)(Up to approximately 24 months)
- ADA (anti-drug antibody)(Up to approximately 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06223841SUNHO（China）BioPharmaceutical CO., Ltd.50
招募中
1 期
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationNon Small Cell Lung CancerNCT05641493Shanghai Henlius Biotech49
已完成
1 期
A Multiple Ascending Dose Trial of CVL-231 in Subjects With SchizophreniaSchizophreniaNCT04136873Cerevel Therapeutics, LLC130
已完成
1 期
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT06281704Akeso34
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNegative Symptoms in SchizophreniaNCT06107803Minerva Neurosciences17